Abstract
We describe a simplified Bayesian analysis of vaccine trial data, in which a reparametrization of the Poisson likelihood leads to a factorization in which the protective vaccine efficacy VES and the nuisance parameter appear in different factors. As a consequence the posterior density acquires a factorized form, and marginalization over the nuisance parameter is trivial. Estimates of VES accordingly become a matter of simple manipulations of one-dimensional posterior probability densities. We demonstrate the method using the publically-released data on the efficacy of three vaccines agains SARS-CoV-2: the final Phase III data from the Pfizer/BioNTech and Moderna mRNA vaccines and the interim data released for the Sputnik V adenovirus-based vaccine.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This material is based upon work supported by the U.S. Department of Energy, Office of Science, under contract number DE-AC02-06CH11357.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data utilized in this manuscript is in the public domain. Hence no approval or exemption is required.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data utilized in this manuscript has been publically released by the companies involved.